Shares of Meta Material, formerly Torchlight, rise 6%
Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin,…